Modelling the COVID-19 epidemic and implementation of population-wide interventions in Italy
暂无分享,去创建一个
[1] W. O. Kermack,et al. A contribution to the mathematical theory of epidemics , 1927 .
[2] A. J. Hall. Infectious diseases of humans: R. M. Anderson & R. M. May. Oxford etc.: Oxford University Press, 1991. viii + 757 pp. Price £50. ISBN 0-19-854599-1 , 1992 .
[3] O. Diekmann,et al. Mathematical Epidemiology of Infectious Diseases: Model Building, Analysis and Interpretation , 2000 .
[4] Herbert W. Hethcote,et al. The Mathematics of Infectious Diseases , 2000, SIAM Rev..
[5] F. Brauer,et al. Mathematical Models in Population Biology and Epidemiology , 2001 .
[6] Michelle M. Packard,et al. Prior Infection and Passive Transfer of Neutralizing Antibody Prevent Replication of Severe Acute Respiratory Syndrome Coronavirus in the Respiratory Tract of Mice , 2004, Journal of Virology.
[7] M. E. Alexander,et al. Modelling strategies for controlling SARS outbreaks , 2004, Proceedings of the Royal Society of London. Series B: Biological Sciences.
[8] C. Furlanello,et al. Mitigation Measures for Pandemic Influenza in Italy: An Individual Based Model Considering Different Scenarios , 2008, PloS one.
[9] Maimuna S. Majumder,et al. Estimation of MERS-Coronavirus Reproductive Number and Case Fatality Rate for the Spring 2014 Saudi Arabia Outbreak: Insights from Publicly Available Data , 2014, PLoS currents.
[10] Pejman Rohani,et al. Avoidable errors in the modelling of outbreaks of emerging pathogens, with special reference to Ebola , 2014, Proceedings of the Royal Society B: Biological Sciences.
[11] R. Webby,et al. Longitudinal study of Middle East Respiratory Syndrome coronavirus infection in dromedary camel herds in Saudi Arabia, 2014–2015 , 2017, Emerging Microbes &Infections.
[12] K. Subbarao,et al. Enhanced inflammation in New Zealand white rabbits when MERS-CoV reinfection occurs in the absence of neutralizing antibody , 2017, PLoS pathogens.
[13] P. Spigaglia,et al. Microbiological characteristics of human and animal isolates of Clostridioides difficile in Italy: Results of the Istituto Superiore di Sanità in the years 2006-2016. , 2019, Anaerobe.
[14] T. Velavan,et al. The COVID‐19 epidemic , 2020, Tropical medicine & international health : TM & IH.
[15] Dan Xu,et al. Positive RT-PCR Test Results in Patients Recovered From COVID-19. , 2020, JAMA.
[16] H. Fineberg. Ten Weeks to Crush the Curve. , 2020, The New England journal of medicine.
[17] H. G. Liu,et al. [Cause analysis and treatment strategies of "recurrence" with novel coronavirus pneumonia (covid-19) patients after discharge from hospital]. , 2020, Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases.
[18] Estimating clinical severity of COVID-19 from the transmission dynamics in Wuhan, China , 2020, Nature Medicine.
[19] Yuyi Wang,et al. Unique epidemiological and clinical features of the emerging 2019 novel coronavirus pneumonia (COVID‐19) implicate special control measures , 2020, Journal of medical virology.
[20] Maria Elena Bottazzi,et al. The SARS-CoV-2 Vaccine Pipeline: an Overview , 2020, Current Tropical Medicine Reports.
[21] P. Vollmar,et al. Transmission of 2019-nCoV Infection from an Asymptomatic Contact in Germany , 2020, The New England journal of medicine.
[22] L. Meyers,et al. Serial Interval of COVID-19 among Publicly Reported Confirmed Cases , 2020, Emerging infectious diseases.
[23] G. Remuzzi,et al. COVID-19 and Italy: what next? , 2020, The Lancet.
[24] Francesco Casella. Can the COVID-19 epidemic be managed on the basis of daily data? , 2020, ArXiv.
[25] Anne Kimball,et al. Asymptomatic and Presymptomatic SARS-CoV-2 Infections in Residents of a Long-Term Care Skilled Nursing Facility — King County, Washington, March 2020 , 2020, MMWR. Morbidity and mortality weekly report.
[26] Bo Diao,et al. Reduction and Functional Exhaustion of T Cells in Patients With Coronavirus Disease 2019 (COVID-19) , 2020, Frontiers in Immunology.
[27] Min Kang,et al. SARS-CoV-2 Viral Load in Upper Respiratory Specimens of Infected Patients , 2020, The New England journal of medicine.
[28] Yongli Cai,et al. A conceptual model for the coronavirus disease 2019 (COVID-19) outbreak in Wuhan, China with individual reaction and governmental action , 2020, International Journal of Infectious Diseases.
[29] Victor M Corman,et al. Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR , 2020, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.
[30] J. Dowd,et al. Demographic science aids in understanding the spread and fatality rates of COVID-19 , 2020, Proceedings of the National Academy of Sciences.
[31] P. Klepac,et al. Feasibility of controlling COVID-19 outbreaks by isolation of cases and contacts , 2020, The Lancet Global Health.
[32] Julian Peto,et al. Covid-19 mass testing facilities could end the epidemic rapidly , 2020, BMJ.
[33] Shaoqiang Li,et al. Development and clinical application of a rapid IgM‐IgG combined antibody test for SARS‐CoV‐2 infection diagnosis , 2020, Journal of medical virology.
[34] R. Jiang,et al. Clinical features of pediatric patients with COVID-19: a report of two family cluster cases , 2020, World Journal of Pediatrics.
[35] P. Klepac,et al. Early dynamics of transmission and control of COVID-19: a mathematical modelling study , 2020, The Lancet Infectious Diseases.
[36] Zunyou Wu,et al. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. , 2020, JAMA.
[37] N. Linton,et al. Serial interval of novel coronavirus (COVID-19) infections , 2020, International Journal of Infectious Diseases.
[38] Wu Zhong,et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro , 2020, Cell Research.
[39] Potential Therapeutic Agents for COVID-19 Based on the Analysis of Protease and RNA Polymerase Docking , 2020 .
[40] J. Hyman,et al. Short-term Forecasts of the COVID-19 Epidemic in Guangdong and Zhejiang, China: February 13–23, 2020 , 2020, Journal of clinical medicine.
[41] Yunpeng Ji,et al. Potential association between COVID-19 mortality and health-care resource availability , 2020, The Lancet Global Health.
[42] L. Yang,et al. Preliminary estimation of the basic reproduction number of novel coronavirus (2019-nCoV) in China, from 2019 to 2020: A data-driven analysis in the early phase of the outbreak , 2020, International Journal of Infectious Diseases.
[43] K. Yuen,et al. Clinical Characteristics of Coronavirus Disease 2019 in China , 2020, The New England journal of medicine.
[44] C. Anastassopoulou,et al. Data-based analysis, modelling and forecasting of the COVID-19 outbreak , 2020, PloS one.
[45] Michael McAleer,et al. Risk Management of COVID-19 by Universities in China , 2020, Journal of Risk and Financial Management.
[46] D. Cummings,et al. Novel coronavirus 2019-nCoV: early estimation of epidemiological parameters and epidemic predictions , 2020, medRxiv.
[47] Liang Peng,et al. Recurrence of positive SARS-CoV-2 RNA in COVID-19: A case report , 2020, International Journal of Infectious Diseases.
[48] A. H. Y. Ma,et al. COVID-19 Transmission Within a Family Cluster by Presymptomatic Carriers in China , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[49] Yan Bai,et al. Presumed Asymptomatic Carrier Transmission of COVID-19. , 2020, JAMA.
[50] Zheng Zhao,et al. Investigation of three clusters of COVID-19 in Singapore: implications for surveillance and response measures , 2020, The Lancet.